

UNIVERSITY OF LEEDS

This is a repository copy of *IFNλ Stimulates MxA Production in Human Dermal Fibroblasts via a MAPK-Dependent STAT1-Independent Mechanism*.

White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/89873/

Version: Accepted Version

Article:

Alase, AA, El-Sherbiny, Y orcid.org/0000-0003-4791-3475, Vital, EM orcid.org/0000-0003-1637-4755 et al. (3 more authors) (2015) IFNλ Stimulates MxA Production in Human Dermal Fibroblasts via a MAPK-Dependent STAT1-Independent Mechanism. Journal of Investigative Dermatology, 135 (12). pp. 2935-2943. ISSN 0022-202X

https://doi.org/10.1038/jid.2015.317

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.

eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/

IFNλ stimulates MxA production in human dermal fibroblasts via a MAPK-dependent STAT1-independent mechanism

Adewonuola Alase[1], Yasser El-Sherbiny[2,6], Edward Vital[2], Desmond J. Tobin[1], Neil A. Turner[4], Miriam Wittmann[1,2,3,5]

[1]Centre for Skin Sciences, Faculty of Life Sciences, University of Bradford, UK

[2]Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, UK

[3]Bradford Teaching Hospitals NHS Foundation Trust, St Luke's Hospital, Department of Dermatology, Bradford, UK

[4]Division of Cardiovascular and Diabetes Research, Leeds Institute for Cardiovascular and Diabetes Research (LICAMM), Faculty of Medicine and Health, University of Leeds, UK

[5]National Institute of Health Research (NIHR), Leeds Musculoskeletal Biomedical Research Unit, Chapel Allerton Hospital, Leeds

[6]Clinical Pathology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt

Corresponding author:

Adewonuola Alase

Room H37, Richmond Building

Centre for Skin Sciences

Faculty of Life Sciences

University of Bradford, UK

BD7 1DP

a.a.alase@student.bradford.ac.uk

Keywords:

Type III IFN, dermal fibroblasts, Stat1, p38 MAPK, lupus erythematosus

Abbreviations

GBP-1, guanulate binding protein 1; IFN, interferon; MxA, myxovirus protein A; MAPK, mitogen activated protein kinase; STAT1, signal transducer and activator of transcription.

Abstract

Interferon lambda (IFNλ) is important for epidermal defence against viruses. It is produced by, and acts on, keratinocytes, whereas fibroblasts were previously considered to be unresponsive to this type III IFN.

Herein we report findings revealing cell type-specific differences in IFNλ signalling and function in skin resident cells. In dermal fibroblasts, IFNλ induced the expression of MxA, a potent antiviral factor, but not other IFN signature genes as it does in primary keratinocytes. In contrast to its effect on keratinocytes, IFNλ did not phosphorylate STAT1 in fibroblasts, but instead activated MAPKs. Accordingly, inhibition of MAPK activation (p38 and p42/44) blocked the expression of MxA protein in fibroblasts but not in keratinocytes. Functionally, IFNλ inhibited proliferation in keratinocytes but not in fibroblasts. Moreover, IFNλ upregulated the expression of TGFβ1-induced collagens in fibroblasts. Taken together, our findings identify primary human dermal fibroblasts as responder cells to IFNλ. Our study shows cutaneous cell type-specific IFN signalling and suggests that IFNλ, whilst important for epidermal anti-viral competence, may also have a regulatory role in the dermal compartment balancing type I IFN-induced inhibition of tissue repair processes.

Introduction

Fibroblasts and keratinocytes are the main tissue cell types found in the dermis and epidermis respectively. While many recent studies have identified the immunological role of keratinocytes, the role of dermal fibroblasts in host defence and inflammatory diseases are only beginning to emerge. Furthermore, dermal fibroblasts synthesise extracellular matrix including collagens (Xu *et al.*, 2009) and thus play an important role in maintaining skin structure and wound healing. Interferon lambda (IFNλ) is a type III IFN comprising four members, IFNλ1 (IL-29), IFNλ2 (IL-28A), IFNλ3 (IL-28B) and IFNλ4 (Kotenko *et al.*, 2003; Prokunina-Olsson *et al.*, 2013; Sheppard *et al.*, 2003). IFNλ belongs to the IL-10 family of cytokines along with IL-10, IL-19, IL-20, IL-22, IL-24 and IL-26. IFNλ uses the heterologous receptor complex comprising IFNλR1 (also known as IL-28Rα1) and the ubiquitously expressed IL-10 receptor 2 (IL-10Rβ) which is also used by IL-10, IL-22 and IL-26 as a second receptor subunit (Kotenko *et al.*, 2003; Sheppard *et al.*, 2003). IFNλR1 is the signalling subunit and so its presence determines cellular responsiveness. Although IFNλ is structurally related to IL-10, it resembles type I IFNs in its antiviral and antiproliferative functions (Miknis *et al.*, 2010). They both signal mainly through the recruitment and activation of members of the Janus family of kinases, JAK1/TYK2 leading to the phosphorylation of signal transducer and activator of transcription (STAT) 1/2 and subsequently to induction of a set of downstream genes known as IFN-stimulated genes (ISGs) such as Myxovirus protein A (MxA), Guanylate binding protein 1 (GBP-1), 2,5-oligoadenylate synthetase (2,5-OAS) and IFN inducible protein 16 (IFI16) with potent antiviral activities (Ank *et al.*, 2008; Sommereyns *et al.*, 2008). Beyond JAK/STAT activation, type I IFNs have also been found to activate MAPK (p38 and ERK (p42/p44) MAPK) which allows for full activation of downstream ISGs (Nguyen *et al.*, 2000; Uddin *et al.*, 2000); and possibly downstream phosphorylation of STAT1 on serine 727 (Goh *et al.*, 1999).

Type I IFNs signal through membrane associated IFNAR1 and IFNAR2 (Lutfalla *et al.*, 1995). While the two subunits of IFNAR are present on all nucleated cell types, IFNλR1 is selectively expressed and functional in certain cell types only (Dickensheets *et al.*, 2013;

Kotenko *et al.*, 2003; Witte *et al.*, 2009; Zahn *et al.*, 2010). Witte et al. described the presence of IL-28Rα1 mRNA expression in human dermal fibroblasts. However, it was observed that these cells were unresponsive to IFNλ, and this was attributed to the very low expression level of the receptor in these cells (Lasfar *et al.*, 2011; Witte *et al.*, 2009).

IFNλ is the main IFN produced by keratinocytes and production of varying amounts of this cytokine has been reported also in other cell types (Wolk *et al.*, 2013; Yin *et al.*, 2012; Zahn *et al.*, 2010). Keratinocytes are susceptible to IFNλ1 and this cytokine substantially contributes to the antiviral competence of the human epidermis (Wolk *et al.*, 2013). Apart from antiviral properties, both types I and III IFNs are known for their pro-apoptotic and anti-proliferative activities (Abushahba *et al.*, 2010; Maher *et al.*, 2008; Steen and Gamero, 2010). These activities have been linked to the ability of IFNs to phosphorylate STAT1 (Zitzmann *et al.*, 2006). High expression of ISGs such as CXCL9, CXCL10, MxA and GBP-1 has been reported in interface dermatitis conditions such as cutaneous lupus erythematosus (CLE) and here increased expression is linked with disease severity (Naschberger *et al.*, 2010; Wenzel *et al.*, 2005).

In this study, we sought to understand if human dermal fibroblasts are responsive to IFNλ1 through the activation of STAT1 and subsequent downstream induction of ISGs. We also wanted to understand the role of this cytokine in maintenance of skin integrity with regard to collagen expression and proliferation of skin resident cells.

Results

IFNλR1 is expressed by human dermal fibroblasts

In order to confirm the expression of IFNλR1 in fibroblasts and to investigate its regulation, fibroblasts were stimulated for 4 or 16 hours for analysis of mRNA and protein expression, respectively. mRNA expression was measured by qPCR and protein expression was measured by Western blotting and flow cytometry. We found that IFNλR1 was expressed in dermal fibroblasts and was upregulated in the presence of IFNα (Figure 1a-e and S1).

IFNλ induces significant expression of MxA in human dermal fibroblasts

To investigate if IFNλR1 is functional in human dermal fibroblasts, cells were treated with rhIFNλ or rhIFNα (positive control) for 4 or 24 hours. mRNA expression of ISGs was quantified using qRT-PCR. We found significant expression of MxA but not GBP-1 (Figure 2), OAS2 (Figure S2) or other analysed ISGs (CXCL9 and IFI-16) after 4 and 24 hours of IFNλ1 treatment. As expected, when compared to IFNλ1, IFNα induced significantly higher expression of MxA and GBP-1 after 4 hours of treatment (Figure 2a-d). However, while the expression of MxA remained high after 24 hours of treatment with IFNα, GBP-1 expression dropped significantly over this time period (Figure 2). In fibroblasts, IFNα appeared to induce higher upregulation of MxA as compared to GBP-1 (Figure 2). IFNλ1 was shown to have a dose-dependent effect on MxA expression in dermal fibroblasts (Figure S3).

IFNα and IFNλ induce ISG expression in human primary keratinocytes

We compared our findings on ISGs expression in fibroblasts with the expression pattern in human primary keratinocytes. The responsiveness of keratinocytes to both type I and III IFNs is well documented (Bachmann *et al.*, 2013; Zahn *et al.*, 2011; Zahn *et al.*, 2010). We found that both IFNα and IFNλ1 induced significant mRNA expression of MxA, OAS2 and GBP-1 with a higher induction of MxA as compared to OAS2 and GBP-1 (Figure 2 and Figure S2). Interestingly, we observed a different time kinetic for the ISG response to IFNα

as compared to IFNλ1. IFNα showed a strong upregulation of MxA and GBP-1 at 6 hours, while IFNλ1 stimulation resulted in a strong increase in MxA and GBP-1 expression between 6 and 24 hours. This suggests that IFNλ1 stimulation may result in more delayed and/or longer lasting effects (Figure 2) as previously observed in hepatocytes (Bolen *et al.*, 2014).

IFNλ activates p38 and ERK MAPKs but not STAT1 (Tyr701) in human dermal fibroblasts

Having established that dermal fibroblasts respond to IFNλ1, we were interested in understanding their mechanism of action. To achieve this, dermal fibroblasts were treated with either IFNλ1 or IFNα for different time points and protein phosphorylation was determined using western blotting. As expected, IFNα-induced STAT1 phosphorylation with maximal phosphorylation detected after 30 minutes of stimulation (Figure 3a). However, we failed to observe any STAT1 phosphorylation in IFNλ1 treated cells in any of the time points investigated. Published studies have reported that phosphorylation of p38 may be necessary for full activation of STAT1 dependent genes (Goh *et al.*, 1999; Platanias, 2003; Uddin *et al.*, 2000). We therefore investigated the ability of IFNλ1 to induce the phosphorylation of p38 in dermal fibroblasts and clearly found activation of this MAPK (Figure 3a). We confirmed that IFNα treatment resulted in p38 phosphorylation in addition to STAT1 phosphorylation (Figure 3a). Furthermore, we found that both IFNα and IFNλ1 induced phosphorylation of ERK (Figure 3a), but not the Akt (p60) (data not shown) pathway in dermal fibroblasts. As expected, we found that both IFNα and IFNλ1 induced STAT1 phosphorylation in primary keratinocytes (Figure 3b). However, we failed to observe clear IFNλ dependent activation of either the p38 or ERK pathway upon treatment with IFNs (Figure 3b).

P38 and ERK inhibitors attenuate IFNλ1-induced MxA protein expression

We sought to understand if the activation of p38 and ERK was responsible for the induction of MxA expression in dermal fibroblasts. To investigate this, fibroblasts were pretreated with p38 (10 μM SB203580) or ERK inhibitors (30 μM PD98059 or 10 μM U0126) for 1 hour prior

to treatment with IFNλ1 or IFNα. mRNA and protein expression were measured by qRT-PCR and Western blotting, respectively. Interestingly, our results showed that the expression of MxA was not regulated at the mRNA level by the MAPK inhibitors (Figure 4a/b). However, the presence of either the p38 or ERK inhibitor abrogated IFNλ1-induced MxA protein production (Figure 4c). We did not observe a decrease in IFNα-induced MxA protein production in fibroblasts in the presence of SB203580, PD98059 (not shown) or U0126 (Figure 4d). We also analysed whether MAPKs played a role in IFNλ1-induced MxA protein expression in human primary keratinocytes. We failed to find a significant effect of p38 or ERK inhibition on IFNλ1 and IFNα-induced MxA protein production in keratinocytes (Figure 4e).

IFNλ enhances collagen expression in human dermal fibroblasts

As conditions with high type I IFN expression can be linked to impaired healing responses, we investigated whether IFNλ1 had any influence on collagen expression. Fibroblasts were treated with IFNλ1, IFNα, TGFβ1 or a combination of IFN and TGFβ1 for 6 or 24 hours. TGFβ1 was used as a control, given its well described stimulation of fibroblast proliferation and collagen synthesis. We measured *Col1A1*, *Col3A1*, *Col4A2* and *Col7A1* using qRT-PCR. There was no difference in collagen expression after 6 hours of stimulation with these cytokines (data not shown). However, after 24 hours of treatment, TGFβ1 significantly induced the expression of these collagens. Combined treatment of cells with IFNλ1 and TGFβ1 resulted in a significantly higher expression of these collagens (except for *Col3A1)* than with either treatment alone (Figure 5a-d). To investigate which of the MAPK pathways may be responsible for the synergy, we treated cultured dermal fibroblasts with either IFNλ1 or TGFβ1 or both together for 30 minutes and analysed for the phosphorylation of p38 and ERK by Western blotting. We found that both IFNλ1 and TGFβ1 activated the p38 and ERK pathways independently (Figure S4). Interestingly, we observed a clear synergistic effect between IFNλ1 and TGFβ1 on the activation of the p38 pathway. The effect is not very clear

with the ERK pathway (Figure S4). This suggests that the p38 pathway may be responsible for the synergistic effect observed on collagen expression.

IFNλ has potent anti-proliferative activity in primary keratinocytes but not in dermal fibroblasts

The anti-proliferative effect of IFNλ1 on HaCaT keratinocyte cell lines has been described (Maher *et al.*, 2008). We aimed to compare the effect of both IFNλ1 and IFNα on primary skin cells. Keratinocytes and fibroblasts were stained with cell tracer dye and subsequently stimulated with either IFNλ or IFNα for 72 hours. As expected, both IFNs clearly reduced keratinocyte proliferation (Figure 6a/b). By contrast, we observed that IFNα but not IFNλ1 inhibited dermal fibroblast proliferation (Figure 6c/d). TGFβ1, known to induce fibroblast proliferation, was used as positive control (Figure 6c/d).

We also investigated the effects of IFNλ1 and IFNα on "gap" closure in monolayer cultures of dermal fibroblasts. We observed the trend that IFNλ1 enhanced gap closure in fibroblasts while IFNα delayed gap closure after 48 hours of stimulation in comparison to the untreated cells (Figure S5).

Discussion

Type I and III, innate IFNs were initially identified for their potent antiviral activities (MacMicking, 2012; Sadler and Williams, 2008). In addition, IFNs also have immunoregulatory, anti-proliferative and pro-apoptotic properties; they have been identified as potential anticancer drugs (Abushahba *et al.*, 2010; Witte *et al.*, 2010). However, they are also important mediators in the pathogenesis of autoimmune diseases such as cutaneous lupus erythematosus (Meyer, 2009; Ronnblom and Eloranta, 2013). MxA is a highly inducible ISG and one of the most potent anti-viral factors capable of blocking early replication events of different RNA and DNA viruses (Sadler and Williams, 2008).

Type III IFN is the most recently described group of IFNs. Expression of their specific receptor was thought to be restricted mainly to epithelial cells (keratinocytes) and hepatocytes. There is, however, emerging evidence that IFNλR1 is also present and functional on hematopoietic cells (Dai *et al.*, 2009; Liu *et al.*, 2011; Mennechet and Uze, 2006; Yin *et al.*, 2012). There are reports identifying MAPKs as regulators of IFN downstream activities (Gough *et al.*, 2008; Uddin *et al.*, 2000; van Boxel-Dezaire *et al.*, 2006) and the importance of different (non JAK) kinases activated in response to IFNs has been speculated before to contribute to cell-type and IFN subtype specific responses (van Boxel-Dezaire *et al.*, 2006). Our work shows a distinct signalling and also functional response of primary human fibroblasts to IFNλ, which is different from the response of these cells to type I IFN and clearly different from the response of epidermal cells. Indeed, keratinocytes show a similar signalling and functional response to both type I and type III IFNs which is characterised by a STAT1-dependent upregulation of a broad range of ISGs. Dermal fibroblasts were considered unresponsive to IFNλ (Abushahba *et al.*, 2010). We here show that human fibroblasts indeed respond to IFNλ1 treatment with significant expression of MxA mRNA and protein. In line with our findings, a recent study has reported the responsiveness of CMV infected foreskin fibroblast to IFNλ3 (Egli *et al.*, 2014). It is well documented that type I and III IFNs induce similar sets of ISGs in many cell types (Ank *et al.*, 2008; Sommereyns *et al.*, 2008). However, in fibroblasts, we failed to observe significant

expression of GBP-1, OAS2 or other ISGs upon IFNλ1 treatment. The inability of IFNλ1 to activate STAT1 (Tyr701) in fibroblasts was unexpected as this is the known canonical pathway for the induction of downstream ISG genes. However, our findings on IFNλ1 induced activation of both p38 and ERK suggest that the MAPK pathway may be an alternative for the induction of MxA by IFNλ in fibroblasts. It has been suggested that IFNα-induced phosphorylation of MAPKs and STAT1 are independent of each other; however, they work in tandem to ensure full activation of ISGs (Li *et al.*, 2004). It is interesting that the inhibition of p38 and ERK in IFNα treated dermal fibroblasts did not result in significant downregulation of MxA protein expression; although we observed a slight reduction in MxA production by primary keratinocytes following inhibition of ERK but not p38. Activation of PI3K-AKT and Raf-MEK-ERK pathways by IFNλ1 and IFNα in HepG2.2.15 cell lines has been reported (Chai *et al.*, 2011), but we could not observe AKT pathway activation in our experiments. Our proposed mechanism of IFNα and IFNλ1 signalling in dermal fibroblasts is shown in Figure S6. To our surprise, we failed to observe any significant regulatory effects of the MAPK inhibitors at the transcriptional level suggesting that p38 and ERK inhibition results in posttransciptional regulation of MxA. Mechanisms of mRNA translation of ISGs have recently been reviewed (Joshi *et al.*, 2010). Both the p38 and p42/44 MAPKs can control the activation of eIF4E and other substrates of MAPK interacting protein kinases 1 and 2 (Mnk1 and 2) which influence translation initiation (Joshi *et al.*, 2010). Posttransriptional regulation of TNFα gene expression in the presence of p38 inhibitor has been described (Clark *et al.*, 2003). Future experiments will need to further dissect the underlying events of the posttranscriptional regulation observed for MxA in dermal fibroblasts. In this study, we have confirmed previous report that human dermal fibroblasts express IFNλR1 (Witte *et al.*, 2009) and that IFNα can upregulate its expression. The ability of IFNα to enhance the expression levels of IFNλR1 is evidence for a cross-talk between type I and type III IFNs (Duong *et al.*, 2014).

TGFβ1 is well known to induce collagen expression in fibroblasts. Types I, III, IV and VII collagens are the main ECM components, basement membrane zone and the anchoring

fibrils at the dermal-epidermal junction (Tiedtke, 2007). We found that IFNλ1 potentiated the TGFβ-associated induction of collagen I, IV and VII most probably by synergistic effect with TGFβ1 on p38 activation. This effect was not observed for collagen type III expression. IFNγ, a type II IFN exhibited an inhibitory effect on TGFβ1-induced ECM or collagen deposition in primary human lung (Eickelberg *et al.*, 2001) and in human foreskin fibroblasts (Ghosh *et al.*, 2001). Of interest, keloid-derived dermal fibroblasts seem non-responsive to this IFNγ-dependent type I collagen regulation (Hasegawa *et al.*, 2003). Excessive secretion of type I collagen is linked with hypertrophic scar formation, while a sufficient amount of type III collagen may prevent scar formation (Oliveira *et al.*, 2009). The net effect of IFNλ1 on cutaneous repair and healing responses is not clear yet and needs to be further investigated. The ability of IFNλ1 to upregulate the expression of type IV (*Col4A2*) and VII collagens (*Col7A1*) suggests that is may support basement membrane integrity (Nystrom *et al.*, 2013).
Our proliferation assay results in primary keratinocytes are consistent with the roles of IFNα and IFNλ1 as anti-proliferative agents. However, we show that IFNλ1 does not have an inhibitory effect on dermal fibroblasts' proliferation and this may be due to its inability to induce STAT1 phosphorylation in these cells. In addition, the anti-proliferative ability of GBP-1 on intestinal epithelial cells has been described (Capaldo *et al.*, 2012) and IFNλ1 failed to induce GBP-1 expression in dermal fibroblasts.
In summary, this study has shown that IFNλR1 is active in dermal fibroblasts through the activation of p38 and ERK pathways. We have shown that MxA induction by IFNλ1 occurs through a STAT1-independent pathway and this may also explain the role of this cytokine in enhancement of collagen expression and lack of anti-proliferative activity. We suggest that the physiologic role of IFNλ activity in the skin organ is certainly linked with viral defence. Keratinocytes as outer barrier cells are main producers of IFNλ. An infection beyond the epidermal compartment will lead to increased expression of antiviral type I IFNs which in turn increase the susceptibility of fibroblasts to epidermal type III IFNs. Dermal fibroblasts will contribute to the antiviral competence of the skin tissue by upregulation of MxA protein but may play an important part in maintaining tissue integrity and allowing repair processes in

the context of damage caused by a viral infection to the basement membrane and type I collagen; as well as mesenchymal cell proliferation. This “repair” phenotype may manifest with some delay in the inflammatory anti-viral response once the more potent, but shorter signalling effect of type I IFNs decreases. This suggested “regulatory” role of type III IFNs on dermal tissue cells is supported by findings from Egli et al who described that in CMV treated foreskin derived fibroblast cell lines, IFNλ exerts an inhibitory action on IFNα induced activity (Egli *et al.*, 2014). We propose that the dermal response to IFNλ1 could counteract type I IFN induced impairment of repair mechanisms. With regard to CLE where IFNλ is highly expressed, our current data do not support a prominent role of IFNλ in repair failure and anti-proliferative activity seen in discoid CLE (Nyberg *et al.*, 2000). However, further experiments regarding functional analysis of skin lesion derived cells would be necessary to verify this assumption.

Materials and Methods

Cytokine and antibodies

Recombinant human (rh) IFNλ1 (100 ng/ml) was purchased from ebioscience (Hatfield, UK); rhIFNα2a (10 ng/ml; Merck Millipore, Merck Serono Ltd, Middlesex, UK), rhTGFβ1 (5 ng/ml; Peprotech EC Ltd, London, UK). Anti-human (rabbit phospho p38, mouse phospho ERK, mouse ERK, rabbit p38, rabbit phospho STAT1 and rabbit STAT1) antibodies were purchased from Cell signalling Technology (Leiden, The Netherlands); anti-human (rabbit MxA, rabbit IFNλR1 and mouse GAPDH) antibodies were purchased from Abcam (Cambridge, UK) and Santa Cruz (Insight Biotechnology Ltd, Middlesex, UK) respectively. Horseradish peroxidase (HRP) conjugated donkey anti-rabbit and donkey anti-mouse secondary antibodies were from Santa Cruz. PD98059, U0126 (MEK/ERK inhibitors) and SB203580 (p38 inhibitor) were from Cell Signalling Technology.

Cell Isolation, Culture and Ethics

Keratinocytes and dermal fibroblasts were derived from skin tissue from anonymised healthy volunteers undergoing cosmetic surgery. Samples were collected following written informed consent by patients and local research ethical approval (Ethical Tissue, University of Bradford). Skin samples were processed on the day of collection. Fibroblasts were isolated by placing the trypsinized dermis in a T75 culture flask; ensuring the upper layer just below the epidermis adhered firmly to the flask. 10 ml DMEM containing 10% FBS was carefully added to the flask so as not to allow the dermis to float. Fibroblasts explanted after 5 to 7 days. Full details are given in supplementary information.

Cell Stimulation

Keratinocytes or fibroblasts were seeded into 24-well or 6-well and allowed to grow to ~ 80% confluency. For keratinocytes, culture medium was replaced with KGM without human epidermal growth factor and hydrocortisone (KGM -/-) prior to cell treatment with cytokines. Dermal fibroblasts were starved of serum for 24 hour before treatment in serum-free DMEM. For inhibition experiments, cells were pre-treated for 1 hour with 10 μM SB203580 (Cell signalling), 30 μM PD98059 or 10 μM U0126 (Cell signalling) before treatment with IFNα or

IFNλ1. Controls included untreated cells and cells treated with dimethylsulphoxide vehicle (DMSO), SB203580 or PD98059/U0126 alone for 24 hours.

Quantitative RT-PCR

MxA, *GBP-1*, *OAS2*, *IFI-16*, *CXCL9*, *IFNλR1*, *Col1A1*, *Col3A1*, *Col4A2* and *Col7A1* QuantiTect primer assays were obtained from Qiagen (Hilden, Germany) while U6 primer (forward – 5' CTCGCTTCGGCAGCACA 3'; reverse-5' AACGCTTCACGAATTTGC 3') was purchased from Sigma Aldrich, UK. The following parameters were used: Initial heat activation, 95°C for 5 minutes; denaturation, 95°C for 10 seconds; combined annealing and elongation, 60°C for 30 seconds for a 40 cycle run. Data were analysed using the delta-delta ct method. mRNA expression of each gene of interest was normalised to U6snRNA housekeeping gene.

Agarose gel electrophoresis

qPCR products were run at 40 mA for 30 minutes on 2% agarose gel. Image was taken under ultraviolet (UV) light. Full details are given in supplementary information.

Western blotting

Cells were lysed with CelLytic M lysis buffer (Sigma-Aldrich) containing protease inhibitor cocktail (Roche Applied Bioscience, Rotkreuz, Switzerland) and phosphatase inhibitor (Thermo Scientific). 30 µg of total protein was separated on any kDa mini protean gel (BioRad) and proteins were blotted onto 0.2 µm PVDF trans-blot pack (Bio-Rad). Membranes were probed with rabbit anti-human pSTAT1 (1:1000), STAT1 (1:1000), phospho p38 (1:1000), mouse anti-human pERK (1:2000), p38 (1:1000) or GAPDH (1:3000) in TBST containing 5% bovine serum albumin (BSA) overnight at 4°C. Rabbit anti-human MxA (1:1000), IFNλR1 (1:1000) and GAPDH were used in 5% milk PBST overnight at 4°C. Donkey anti-rabbit and donkey anti-mouse HRP-conjugated secondary antibodies were used at 1:5000 and 1:3000 respectively for 1 hour at room temperature. For a repeat Western, membranes were stripped, blocked and re-probed with primary antibody.

Cell trace proliferation assay

Human primary keratinocytes and dermal fibroblasts were stained in KGM or serum-free DMEM respectively with cell trace violet (Molecular probes/Life technologies) away from the source of light (2 µl cell trace to 1 million cells in 1 ml media). Cells were plated in 6 well plates and were either treated with cytokines or untreated for 72 hours. Some cells were used for the day 0 analysis. For flow cytometric analysis, a BD LSRFortessa (BD Bioscience, Oxford, UK) machine was used. Cell proliferation was calculated using ModFit software version 3.2 (Verity Software House, Topsham, ME. USA). Full details are given in supplementary information.

Statistical analysis

Statistical significance was determined using Mann Whitney test or unpaired *t*-test. Analysis was performed using GraphPad Prism software (GraphPad Software Inc. La Jolla, CA, USA). All data are expressed as means ± SEM and values of $p < 0.05$ were considered significant. 'n' represents independent experiments; *p< 0.05, **p< 0.01.

Conflict of Interest

Authors state no conflict of interest

Acknowledgement

We would like to thank The University of Bradford and the Centre for Skin Sciences for PhD funding granted to Adewonuola Alase. Dr Vital is funded by an NIHR Clinician Scientist Fellowship CS-2013-13-032

References

Abushahba W, Balan M, Castaneda I*, et al.* (2010) Antitumor activity of type I and type III interferons in BNL hepatoma model. *Cancer Immunol Immunother* 59:1059-71.

Ank N, Iversen MB, Bartholdy C*, et al.* (2008) An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity. *J Immunol* 180:2474-85.

Bachmann M, Ulziibat S, Hardle L*, et al.* (2013) IFNalpha converts IL-22 into a cytokine efficiently activating STAT1 and its downstream targets. *Biochem Pharmacol* 85:396-403.

Bolen CR, Ding S, Robek MD*, et al.* (2014) Dynamic expression profiling of type I and type III interferon-stimulated hepatocytes reveals a stable hierarchy of gene expression. *Hepatology* 59:1262-72.

Capaldo CT, Beeman N, Hilgarth RS*, et al.* (2012) IFN-gamma and TNF-alpha-induced GBP-1 inhibits epithelial cell proliferation through suppression of beta-catenin/TCF signaling. *Mucosal Immunol* 5:681-90.

Chai Y, Huang HL, Hu DJ*, et al.* (2011) IL-29 and IFN-alpha regulate the expression of MxA, 2',5'-OAS and PKR genes in association with the activation of Raf-MEK-ERK and PI3K-AKT signal pathways in HepG2.2.15 cells. *Mol Biol Rep* 38:139-43.

Clark AR, Dean JL, Saklatvala J (2003) Post-transcriptional regulation of gene expression by mitogen-activated protein kinase p38. *FEBS Lett* 546:37-44.

Dai J, Megjugorac NJ, Gallagher GE*, et al.* (2009) IFN-lambda1 (IL-29) inhibits GATA3 expression and suppresses Th2 responses in human naive and memory T cells. *Blood* 113:5829-38.

Dickensheets H, Sheikh F, Park O*, et al.* (2013) Interferon-lambda (IFN-lambda) induces signal transduction and gene expression in human hepatocytes, but not in lymphocytes or monocytes. *J Leukoc Biol* 93:377-85.

Duong FH, Trincucci G, Boldanova T*, et al.* (2014) IFN-lambda receptor 1 expression is induced in chronic hepatitis C and correlates with the IFN-lambda3 genotype and with nonresponsiveness to IFN-alpha therapies. *J Exp Med* 211:857-68.

Egli A, Levin A, Santer DM*, et al.* (2014) Immunomodulatory Function of Interleukin 28B during primary infection with cytomegalovirus. *J Infect Dis* 210:717-27.

Eickelberg O, Pansky A, Koehler E*, et al.* (2001) Molecular mechanisms of TGF-(beta) antagonism by interferon (gamma) and cyclosporine A in lung fibroblasts. *FASEB J* 15:797-806.

Ghosh AK, Yuan W, Mori Y, *et al.* (2001) Antagonistic regulation of type I collagen gene expression by interferon-gamma and transforming growth factor-beta. Integration at the level of p300/CBP transcriptional coactivators. *J Biol Chem* 276:11041-8.

Goh KC, Haque SJ, Williams BR (1999) p38 MAP kinase is required for STAT1 serine phosphorylation and transcriptional activation induced by interferons. *EMBO J* 18:5601-8.

Gough DJ, Levy DE, Johnstone RW, *et al.* (2008) IFNgamma signaling-does it mean JAK-STAT? *Cytokine Growth Factor Rev* 19:383-94.

Hasegawa T, Nakao A, Sumiyoshi K, *et al.* (2003) IFN-gamma fails to antagonize fibrotic effect of TGF-beta on keloid-derived dermal fibroblasts. *J Dermatol Sci* 32:19-24.

Joshi S, Kaur S, Kroczynska B, *et al.* (2010) Mechanisms of mRNA translation of interferon stimulated genes. *Cytokine* 52:123-7.

Kotenko SV, Gallagher G, Baurin VV, *et al.* (2003) IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. *Nat Immunol* 4:69-77.

Lasfar A, Abushahba W, Balan M, *et al.* (2011) Interferon lambda: a new sword in cancer immunotherapy. *Clin Dev Immunol* 2011:349575.

Li Y, Sassano A, Majchrzak B, *et al.* (2004) Role of p38alpha Map kinase in Type I interferon signaling. *J Biol Chem* 279:970-9.

Liu BS, Janssen HL, Boonstra A (2011) IL-29 and IFNalpha differ in their ability to modulate IL-12 production by TLR-activated human macrophages and exhibit differential regulation of the IFNgamma receptor expression. *Blood* 117:2385-95.

Lutfalla G, Holland SJ, Cinato E, *et al.* (1995) Mutant U5A cells are complemented by an interferon-alpha beta receptor subunit generated by alternative processing of a new member of a cytokine receptor gene cluster. *EMBO J* 14:5100-8.

MacMicking JD (2012) Interferon-inducible effector mechanisms in cell-autonomous immunity. *Nat Rev Immunol* 12:367-82.

Maher SG, Sheikh F, Scarzello AJ, *et al.* (2008) IFNalpha and IFNlambda differ in their antiproliferative effects and duration of JAK/STAT signaling activity. *Cancer Biol Ther* 7:1109-15.

Mennechet FJ, Uze G (2006) Interferon-lambda-treated dendritic cells specifically induce proliferation of FOXP3-expressing suppressor T cells. *Blood* 107:4417-23.

Meyer O (2009) Interferons and autoimmune disorders. *Joint Bone Spine* 76:464-73.

Miknis ZJ, Magracheva E, Li W*, et al.* (2010) Crystal structure of human interferon-lambda1 in complex with its high-affinity receptor interferon-lambdaR1. *J Mol Biol* 404:650-64.

Naschberger E, Wenzel J, Kretz CC*, et al.* (2010) Increased expression of guanylate binding protein-1 in lesional skin of patients with cutaneous lupus erythematosus. *Exp Dermatol* 20:102-6.

Nguyen VA, Chen J, Hong F*, et al.* (2000) Interferons activate the p42/44 mitogen-activated protein kinase and JAK-STAT (Janus kinase-signal transducer and activator transcription factor) signalling pathways in hepatocytes: differential regulation by acute ethanol via a protein kinase C-dependent mechanism. *Biochem J* 349:427-34.

Nyberg F, Fransson J, Stephansson E (2000) Proliferation and effects of UVA irradiation in cultured fibroblasts from lesions in cutaneous lupus erythematosus. *Exp Dermatol* 9:53-7.

Nystrom A, Velati D, Mittapalli VR*, et al.* (2013) Collagen VII plays a dual role in wound healing. *J Clin Invest* 123:3498-509.

Oliveira GV, Hawkins HK, Chinkes D*, et al.* (2009) Hypertrophic versus non hypertrophic scars compared by immunohistochemistry and laser confocal microscopy: type I and III collagens. *Int Wound J* 6:445-52.

Platanias LC (2003) The p38 mitogen-activated protein kinase pathway and its role in interferon signaling. *Pharmacol Ther* 98:129-42.

Prokunina-Olsson L, Muchmore B, Tang W*, et al.* (2013) A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. *Nat Genet* 45:164-71.

Ronnblom L, Eloranta ML (2013) The interferon signature in autoimmune diseases. *Curr Opin Rheumatol* 25:248-53.

Sadler AJ, Williams BR (2008) Interferon-inducible antiviral effectors. *Nat Rev Immunol* 8:559-68.

Sheppard P, Kindsvogel W, Xu W*, et al.* (2003) IL-28, IL-29 and their class II cytokine receptor IL-28R. *Nat Immunol* 4:63-8.

Sommereyns C, Paul S, Staeheli P*, et al.* (2008) IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. *PLoS Pathog* 4:e1000017.

Steen HC, Gamero AM (2010) Interferon-lambda as a potential therapeutic agent in cancer treatment. *J Interferon Cytokine Res* 30:597-602.

Tiedtke JaM, O (2007) Stimulation of collagen production in human dermal fibroblasts. *Costmetic Sci Tech*:15-8.

Uddin S, Lekmine F, Sharma N*, et al.* (2000) The Rac1/p38 mitogen-activated protein kinase pathway is required for interferon alpha-dependent transcriptional activation but not serine phosphorylation of Stat proteins. *J Biol Chem* 275:27634-40.

van Boxel-Dezaire AH, Rani MR, Stark GR (2006) Complex modulation of cell type-specific signaling in response to type I interferons. *Immunity* 25:361-72.

Wenzel J, Uerlich M, Worrenkamper E*, et al.* (2005) Scarring skin lesions of discoid lupus erythematosus are characterized by high numbers of skin-homing cytotoxic lymphocytes associated with strong expression of the type I interferon-induced protein MxA. *Br J Dermatol* 153:1011-5.

Witte K, Gruetz G, Volk HD*, et al.* (2009) Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. *Genes Immun* 10:702-14.

Witte K, Witte E, Sabat R*, et al.* (2010) IL-28A, IL-28B, and IL-29: promising cytokines with type I interferon-like properties. *Cytokine Growth Factor Rev* 21:237-51.

Wolk K, Witte K, Witte E*, et al.* (2013) IL-29 is produced by T(H)17 cells and mediates the cutaneous antiviral competence in psoriasis. *Sci Transl Med* 5:204ra129.

Xu J, Lamouille S, Derynck R (2009) TGF-beta-induced epithelial to mesenchymal transition. *Cell Res* 19:156-72.

Yin Z, Dai J, Deng J*, et al.* (2012) Type III IFNs are produced by and stimulate human plasmacytoid dendritic cells. *J Immunol* 189:2735-45.

Zahn S, Rehkamper C, Ferring-Schmitt S*, et al.* (2011) Interferon-alpha stimulates TRAIL expression in human keratinocytes and peripheral blood mononuclear cells: implications for the pathogenesis of cutaneous lupus erythematosus. *Br J Dermatol* 165:1118-23.

Zahn S, Rehkamper C, Kummerer BM*, et al.* (2010) Evidence for a pathophysiological role of keratinocyte-derived type III interferon (IFNlambda) in cutaneous lupus erythematosus. *J Invest Dermatol* 131:133-40.

Zitzmann K, Brand S, Baehs S*, et al.* (2006) Novel interferon-lambdas induce antiproliferative effects in neuroendocrine tumor cells. *Biochem Biophys Res Commun* 344:1334-41.

Figure legends

1. **IFNλR1 expression and production in human dermal fibroblasts**

   Cultured dermal fibroblasts were either untreated or treated with 10 ng/ml IFNα for 4 or 16 hours in serum-free medium for mRNA and protein expression respectively. mRNA expression was measured using qPCR and protein by Western blotting and flow cytometry. (a) qPCR products for IFNλR1 and housekeeping gene U6snRNA on 2% agarose gel are shown as a representative of five independent experiments. (b) Relative mRNA expression. (c) A representative Western blot result for IFNλR1 protein and (d) protein band intensity analysis are depicted; n=3. (e) A representative (n=3) histogram of flow cytometric analysis of IFNλR1 and appropriate isotype control. For statistical analysis, Mann Whitney U test was used. Values represent mean ± SEM. *p<0.05, **p<0.01. UT: Untreated; K: keratinocytes.

2. **Interferon stimulated gene (ISG)s expression in human skin resident cells**

   Cultured dermal fibroblasts were either untreated or treated with 10 ng/ml IFNα or 100 ng/ml IFNλ1 for 4 or 24 hours in serum-free medium. Primary keratinocytes were treated with the same concentration of cytokines for 6 or 24 hours in KGM (-/-). mRNA expression of ISGs was measured using qRT-PCR. Top panel shows expression levels of MxA, 4 hours; MxA, 24 hours; GBP-1, 4 hours and GBP-1, 24 hours in fibroblasts. Bottom panel shows expression levels of MxA, 6 hours; MxA, 24 hours; GBP-1, 6 hours and GBP-1, 24 hours in keratinocytes. For statistical analysis, Mann Whitney U test was used; n=5, values represent mean ± SEM. *p<0.05, **p<0.01. UT: Untreated.

3. **IFNλ1 induced STAT1 and MAPKs phosphorylation fibroblasts and keratinocytes**

   Cultured human dermal fibroblasts (3a) or primary keratinocytes (3b) were either non treated or treated with 10 ng/ml IFNα or 100 ng/ml IFNλ1 for 10, 30 or 60 minutes. Total and phosphorylated p38, ERK and Stat1 along with GAPDH were detected by Western Blot. A representative out of three independent experiments is depicted. UT: untreated.

4. **Inhibition of MxA production by phospho- p38 and -ERK inhibitors**

   Cultured dermal fibroblasts or primary keratinocytes were either untreated or treated with MAPK inhibitors or IFNs for 4 and 24 hours and MxA was detected on the mRNA level and by Western blot (24 hours). (a) MxA mRNA expression, 4 hours; n=3; (b) MxA mRNA expression, 24 hours; n=3; (c) MxA protein expression by IFNλ1 in the presence or absence of MAPK inhibitors in fibroblasts; (d) MxA protein expression by IFNα in the presence or absence of MAPK inhibitors in fibroblasts; (e) MxA protein expression by IFNλ1 and IFNα in human primary keratinocytes in the presence or absence of MAPK inhibitors. Figures are representative of three independent experiments. SB: SB203580 (p38 inhibitor); U: U0126 (MEK/ERK inhibitors).

5. **Effect of IFNλ of collagen expression in human dermal fibroblasts**

   Cultured dermal fibroblasts were either untreated or treated with 10 ng/ml IFNα, 100 ng/ml IFNλ1, 5 ng/ml TGFβ1 or combination of IFNλ1 and TGFβ1 for 24 hours. mRNA expression of ISGs was measured using qRT-PCR. Depicted is *Col1A1* (a) *Col3A1* (b) *Col4A2* (c) and *Col7A1* (d) expression. For statistical analysis, Mann Whitney U test was used; n=5, values represent mean± SEM. *p<0.05, **p<0.01.

6. **Effects of IFNs on proliferation of skin resident cells**

Dermal fibroblasts or primary keratinocytes were labelled with cell trace violet in DMEM containing 1% FBS and KGM respectively. Plated cells were either untreated or treated with cytokines. Daughter cell populations (highlighted by different colours) of dividing cells were visualised by flow cytometry after 72 hours of stimulation. Increased proliferation results in a shift to the left end of the histogram. (a) Fluorescent signal in keratinocytes at Day 0 and after exposure to IFNλ1/IFNα/medium alone for 72 hours (b) Percentage proliferation of keratinocytes (n=3) (c) Percentage proliferation of fibroblasts (n=3) (d) Fluorescent signal in fibroblasts at day 0 and 72 hours after stimulation with TGFβ/IFNλ1/IFNα/medium. For statistical analysis, unpaired *t* test was used; n=3, values represent mean± SEM. *p<0.05, **p<0.01. UT: Untreated.